 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that the Investigational New Drug Application IND for MN-166 ibudilast for prevention of Acute Respiratory Distress Syndrome ARDS has been accepted and is now open with the U.S. Food and Drug Administration FDA. MediciNova was informed by the FDA that the proposed clinical investigation of MN-166 ibudilast for the prevention of ARDS in patients with COVID-19 may proceed. 